Full-Time

Director – Medical Monitor

Clinical Development, MD

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$276k - $311kAnnually

+ Equity Component

Mid, Senior

Remote in USA

Remote position with a listed location in San Carlos, California.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • MD (active medical license is preferred) with both early and late-stage drug development experience desired. Minimum of 3 years of industry experience required.
  • Exceptional written and oral communication skills to meet the needs of varied audiences.
  • Integrated understanding of FDA, EMA, ICH, and GCP guidelines. Prior interactions with FDA and EMA regulatory agencies are desirable.
  • Attention to detail, internal drive to generate high-quality work, and sense of passion and urgency to achieve team and program goals.
  • Strong analytical, problem-solving skills, and strategic planning skills required.
  • Must be accurate, detailed and committed to high quality standards and proactive in finding solutions to achieve successful outcomes.
  • Highly capable of following organizational plans, goal setting, resource management, contingency planning, coordinating and collaborating with others.
  • The ideal candidate will be a results-driven team player and must thrive in a fast-paced, dynamic environment. Must have the ability to drive results, possessing a strong drive to meet and exceed goals and be willing to take ownership of problems and make or recommend sound decisions.
Responsibilities
  • Provide direct medical monitoring or medical safety oversight of CRO medical monitors.
  • Provide clinical input on protocols, IBs, ICFs, INDs, safety reports, monitoring plans, review forms, data edit checks, and data quality planning.
  • Provide protocol-specific training to the study team and Investigators.
  • Advise the study team on medical issues during risk assessment and mitigation, ensuring quality, compliance, and study participant safety.
  • Work with the study team to ensure protocol adherence and data integrity.
  • Ensure high-quality data by verifying patient population and adequacy of clinical assessments.
  • Review and interpret clinical data on a real-time basis, including report review, teleconferences, and other activities in collaboration with the Clinical Operations and Data Management groups, and make recommendations and determinations as appropriate and required to help ensure the protection of study participants.
  • Responsible for the preparation, analysis, and presentation of safety data as part of the Internal Safety Team (IST) and to the Data Safety Monitoring Board (DSMB).
  • Ensure compliance with regulatory reporting requirements for safety reporting in conjunction with Regulatory Affairs.
  • Represent Vaxcyte externally to trial site Investigators and administrators.
  • Comply with Vaxcyte’s SOPs and adhere to ICH, GCP, and relevant regulatory guidelines.
  • Collaborate on topline data reporting and clinical study reports.
  • Support the study team in issue resolution, study closeout, audit responses, and inspection readiness.
  • Co-author abstracts, posters, presentations, and publications.
  • Develop and maintain strong, collaborative relationships with the broader Vaxcyte organization.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

23%

1 year growth

61%

2 year growth

129%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?